Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Hepatitis B vaccine industry 360º synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 End-use trends
Chapter 3 Hepatitis B Vaccine Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of hepatitis B infection
3.2.1.2 Increasing government initiatives and policies to promote vaccination
3.2.1.3 Rising investments in R&D
3.2.1.4 Increasing focus on preventive healthcare
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulations for the approval of vaccine
3.2.2.2 High cost of vaccine storage and transportation
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By end-use
3.4 COVID- 19 impact analysis
3.5 Technological advancements
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategic outlook matrix
Chapter 5 Hepatitis B Vaccine Market Size and Forecast, By Type (USD Million)
5.1 Key trends, by type
5.2 Single Antigen Vaccine
5.3 Combination Vaccine
Chapter 6 Hepatitis B Vaccine Market Size and Forecast, By End-use (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals
6.3 Clinics
6.4 Others
Chapter 7 Hepatitis B Vaccine Market Size and Forecast, By Region (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Poland
7.3.7 Sweden
7.3.8 The Netherlands
7.3.9 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Indonesia
7.4.7 Philippines
7.4.8 Malaysia
7.4.9 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Columbia
7.5.5 Chile
7.5.6 Peru
7.5.7 Rest of Latin America
7.6 MEA
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Israel
7.6.5 Turkey
7.6.6 Iran
7.6.7 Rest of MEA
Chapter 8 Company Profiles
8.1 Dynavax Technologies Corporation
8.2 Merck & Co., Inc
8.3 GSK plc
8.4 Sanofi S.A.
8.5 VBI Vaccines Inc
8.6 Beijing Minhai Biotechnology Co., Ltd.
8.7 Gilead Sciences, Inc
8.8 Shenzhen Kangtai Biological Products
8.9 Bharat Biotech International Limited
8.10 Serum Institute of India Pvt. Ltd.
8.11 Biological E Limited
